A digital insomnia treatment is designed to help change the behaviours and thinking associated with sleep difficulties. A sleep tracker estimates or summarises sleep. Those are different purposes: a more detailed sleep score does not make a tracker a treatment, and evidence for a treatment does not validate a wearable’s measurements.
Sleepio offers a useful example because NICE has assessed both its clinical evidence and its proposed place in care. The important questions are what it was compared with, who the recommendation covers and how someone can actually access a service.
From observing sleep to a structured programme
Cognitive behavioural therapy for insomnia, usually shortened to CBT-I, is a structured treatment approach. A digital programme delivers therapeutic content and activities through software, rather than simply displaying a nightly rating.
NICE’s technology description sets out weekly interactive sessions and a sleep diary, rather than a score alone. That describes the assessed programme; it is not a promise about every current sleep app.
This changes the evidence question. For a tracker, one might ask how closely an estimate agrees with a reference measurement. For a treatment, the question is whether people receiving it improve compared with a defined alternative, over a stated follow-up period.
The two can coexist in a person’s routine, but one does not establish the value of the other. Our guide to wearable sleep scores explains how selected inputs become ratings and why algorithm changes can alter them.
What NICE recommends—and for whom
NICE’s Sleepio recommendations support it as a cost-saving option for insomnia and insomnia symptoms in primary care for people who would otherwise be offered sleep hygiene or sleeping pills.
The recommendation is conditional on that place in care. NICE also says a medical assessment should precede referral when people may be at higher risk of another sleep disorder, including in pregnancy or with comorbidities. It calls for further research for people eligible for face-to-face CBT-I because the comparative evidence is limited.
The recommendations originated in 2022. Their later appearance under the HTG624 guidance number should not be mistaken for a new 2026 clinical recommendation or a new trial.
Why the comparator changes the meaning
NICE’s evidence assessment describes randomized trials supporting improvement in insomnia symptoms. It also identifies variation in study populations, outcomes and comparison groups, with standard care sometimes poorly described.
An improvement compared with a waiting list or sleep-hygiene information does not establish superiority to another digital programme. Nor does it prove equivalence to face-to-face therapy. Those are separate comparisons that need their own evidence.
The committee discussion preserves that distinction. Economic modelling and clinical comparison also answer different questions: projected resource savings cannot substitute for a directly measured patient outcome.
Recommendation is not the same as universal access
A 2026 NHS implementation example published by NICE describes local insomnia-service provision and uneven digital CBT-I commissioning. It is useful evidence about implementation, rather than a nationwide eligibility or waiting-time directory.
Access depends on the actual service and its current arrangements. A national assessment, a commercial subscription and an NHS referral pathway should not be treated as interchangeable routes.
For someone encountering a digital sleep product, a useful first distinction is whether it measures, offers general information or delivers a structured therapeutic programme. After that come the precise population, comparator, outcome and access route. A compelling app interface cannot answer those questions by itself, and a recommendation for one documented programme should not be transferred to every product calling itself a sleep app.